SGMOs Earnings Miss Sparks 30% Stock Slide Despite Pipeline Progress

Sangamo Therapeutics (SGMO) reported its 2025 Q4 earnings on March 30, 2026, missing revenue and earnings expectations. The company posted a net loss of $37.42 million, a 59.9% increase compared to the previous year, while revenue rose 88.4% year-over-year. Despite progress in its clinical pipeline, Sangamo’s stock declined significantly post-earnings, reflecting investor concerns over financial performance and regulatory uncertainties.

Revenue

Sangamo Therapeutics reported total revenue of $14.23 million for Q4 2025, representing an 88.4% year-over-year increase from $7.55 million in Q4 2024. The growth was driven by continued development and commercialization efforts in its pipeline of gene therapy and epigenetic platform programs. However, the revenue still came in well below analyst expectations of $40.25 million, contributing to the sharp decline in stock price following the earnings release.

Earnings/Net Income

Despite the revenue increase, Sangamo Therapeutics’ financial performance deteriorated on the bottom line. The company posted a net loss of $37.42 million in Q4 2025, representing a 59.9% year-over-year increase in losses from $23.40 million in Q4 2024. On a per-share basis, the loss remained consistent at $0.11 in both periods. This widening loss highlights the company’s ongoing financial challenges and the significant investment required to advance its pipeline.

The EPS performance remains a critical concern, given the lack of meaningful improvement despite increased revenue and continued investment in key programs.

Price Action

Following the earnings report, Sangamo’s stock price declined sharply, with a 9.16% drop on the latest trading day and an 8.27% drop over the most recent full trading week. Month-to-date, the stock has fallen by 30.16%, reflecting broader investor skepticism and the underwhelming earnings report. The poor performance underscores the market’s concern over the company’s financial outlook and regulatory hurdles.

The strategy of buying SGMO shares after the revenue drop quarter-over-quarter on the financial report release date and holding for 30 days resulted in a significant loss. The strategy had a CAGR of -56.27% and an excess return of -138.82%, with a maximum drawdown of 96.61% and a Sharpe ratio of -0.46, indicating it was a high-risk strategy with substantial losses.

CEO Commentary

Alexander Macrae, CEO of Sangamo Therapeutics, highlighted key pipeline progress in 2025, including the release of positive top-line results from the Fabry disease STAR study and the initiation of a rolling BLA submission for ST-920. He emphasized the company’s transition toward a clinical-stage neurology focus through the STAND study and noted the successful securing of $130 million in non-dilutive funding. However, Macrae acknowledged ongoing challenges, such as regulatory uncertainty and limited cash reserves, and identified securing a Fabry commercial partner as a top strategic priority.

Guidance

For 2026, Sangamo provided financial guidance on a GAAP basis, estimating total operating expenses between $120 million and $140 million, including non-cash stock-based compensation and depreciation. On a non-GAAP basis, the company anticipates operating expenses in the range of $110 million to $120 million. The CEO also outlined key near-term goals, including completing the BLA submission for ST-920, advancing the STAND study for small fiber neuropathy, and finalizing CMC work for ST-506. No explicit revenue or EPS guidance was provided, with the focus remaining on strategic and regulatory milestones.

Post-Earnings Price Action Review

Investor sentiment turned sharply negative following the earnings report, as the underwhelming financial results and regulatory uncertainties weighed on the stock. The stock’s decline reflected both the earnings miss and broader concerns about Sangamo’s ability to secure commercial partnerships and achieve key milestones. The market’s reaction underscores the elevated risks associated with biotech firms in early-stage development, particularly those facing cash constraints and regulatory delays. The negative price action highlights the importance of both near-term operational progress and long-term strategic clarity in driving investor confidence.

Additional News

In the weeks following the March 30, 2026 earnings release, Sangamo Therapeutics made several key strategic and operational announcements. The company secured a third neurology capsid license agreement with Eli Lilly, expanding its role as a leading provider of neurotropic capsid technology. Additionally, Sangamo received Fast Track Designation from the FDA for SC503, its investigational epigenetic therapy for small fiber neuropathy, signaling potential for expedited regulatory review. Meanwhile, the company continued its efforts to raise non-dilutive capital, having secured over $130 million through milestone payments, license fees, and equity financing since the start of 2025. These developments underscore Sangamo’s focus on building a sustainable, clinical-stage biotech platform while navigating cash flow and partnership challenges.